Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes

Chemico-Biological Interactions

Volumn 255, Issue , 2016, Pages 31-44

  Terelius, Ylva ^a   Figler, Robert A ^b   Marukian, Svetlana ^b   Collado, Maria S ^b   Lawson, Mark J ^b   Mackey, Aaron J ^b   Manka, David ^b   Qualls, Charles W ^c   Blackman, Brett R ^b   Wamhoff, Brian R ^b   Dash, Ajit ^b  

^a MEDIVIR AB   (Sweden)

^b HemoShear Therapeutics   (United States)

^c Qualls Preclinical Solutions LLC   (United States)

Author keywords

3 D models; DILI; Liver; Nevirapine; Ritonavir; Transcriptomics

Indexed keywords

BILE ACID; NEVIRAPINE; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TRANSCRIPTOME;

ANTIGEN PRESENTATION; ARTICLE; BLOOD FLOW; CD8+ T LYMPHOCYTE; CYP2B6 GENE; CYP3A4 GENE; DOWN REGULATION; DRUG METABOLISM; DRUG RESPONSE; FATTY ACID SYNTHESIS; GENE; GENE EXPRESSION; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; IN VIVO STUDY; NATURAL KILLER CELL; NORMAL HUMAN; RNA SEQUENCE; SIGNAL TRANSDUCTION; TOXIC HEPATITIS; TRANSCRIPTOMICS; UGT1A1 GENE; UPREGULATION; CELL CULTURE; CELL CULTURE TECHNIQUE; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG EFFECTS; GENETICS; LIVER; LIVER CELL; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANTI-HIV AGENTS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; LIVER; NEVIRAPINE; RITONAVIR; TRANSCRIPTOME;

EID: 84954305068     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.11.023     Document Type: Article

References (71)

1. [1] Lee, W.M., Acute liver failure in the United States. Semin. Liver Dis. 23:3 (2003), 217–226.
2. [2] Temple, R.J., Himmel, M.H., Safety of newly approved drugs: implications for prescribing. JAMA 287:17 (2002), 2273–2275.
3. [3] Godoy, P., Hewitt, N.J., Albrecht, U., Andersen, M.E., Ansari, N., Bhattacharya, S., et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 87:8 (2013), 1315–1530.
4. [4] LeCluyse, E.L., Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13:4 (2001), 343–368.
5. [5] Farid, W.R., Pan, Q., van der Meer, A.J., de Ruiter, P.E., Ramakrishnaiah, V., de Jonge, J., et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl. 18:3 (2012), 290–297.
6. [6] Kia, R., Kelly, L., Sison-Young, R.L., Zhang, F., Pridgeon, C.S., Heslop, J.A., et al. MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity. Toxicol. Sci. 144:1 (2015), 173–185.
7. [7] Kobayashi, H., Horikoshi, K., Yamataka, A., Lane, G.J., Watanabe, S., Futagawa, S., et al. alpha-Glutathione-s-transferase as a new sensitive marker of hepatocellular damage in biliary atresia. Pediatr. Surg. Int. 16:4 (2000), 302–305.
8. [8] Borlak, J., Chougule, A., Singh, P.K., How useful are clinical liver function tests in in vitro human hepatotoxicity assays?. Toxicol. Vitr. 28:5 (2014), 784–795.
9. [9] Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268:1 (2013), 1–16.
10. [10] Ware, B.R., Berger, D.R., Khetani, S.R., Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol. Sci. 145:2 (2015), 252–262.
11. [11] Baker, T.K., Carfagna, M.A., Gao, H., Dow, E.R., Li, Q., Searfoss, G.H., et al. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem. Res. Toxicol. 14:9 (2001), 1218–1231.
12. [12] Boess, F., Kamber, M., Romer, S., Gasser, R., Muller, D., Albertini, S., et al. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73:2 (2003), 386–402.
13. [13] Rodriguez-Antona, C., Donato, M.T., Boobis, A., Edwards, R.J., Watts, P.S., Castell, J.V., et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:6 (2002), 505–520.
14. [14] Hoffmaster, K.A., Turncliff, R.Z., LeCluyse, E.L., Kim, R.B., Meier, P.J., Brouwer, K.L., P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm. Res. 21:7 (2004), 1294–1302.
15. [15] Fang, J.L., Beland, F.A., Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine. J. Toxicol. Sci. 38:5 (2013), 741–752.
16. [16] Hastings, N.E., Feaver, R.E., Lee, M.Y., Wamhoff, B.R., Blackman, B.R., Human IL-8 regulates smooth muscle cell VCAM-1 expression in response to endothelial cells exposed to atheroprone flow. Arterioscler. Thromb. Vasc. Biol. 29:5 (2009), 725–731.
17. [17] Hastings, N.E., Simmers, M.B., McDonald, O.G., Wamhoff, B.R., Blackman, B.R., Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am. J. Physiol. Cell Physiol. 293:6 (2007), C1824–C1833.
18. [18] Dash, A., Blackman, B.R., Wamhoff, B.R., Organotypic systems in drug metabolism and toxicity: challenges and opportunities. Expert Opin. Drug Metab. Toxicol. 8:8 (2012), 999–1014.
19. [19] Dash, A., Simmers, M.B., Deering, T.G., Berry, D.J., Feaver, R.E., Hastings, N.E., et al. Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro. Am. J. Physiol. Cell Physiol. 304:11 (2013), C1053–C1063.
20. [20] Controlled hemodynamics maintains metabolic and hepatitis C virus supportive phenotype. Marukian, S., Deering, T.G., Thomas, J., Palmer, S., Terelius, Y., Blackman, B.R., et al. (eds.) Primary Human Hepatocytes, 2013, American Association for the Study of Liver Diseases (AASLD), Washington DC.
21. [21] Physiological hemodynamics and transport restore insulin and glucagon responses in a normal glucose milieu in hepatocytes in vitro. Dash, A., Deering, T.G., Marukian, S., Thomas, J., Wamhoff, B.R., Blackman, B.R., (eds.) 73rd Scientific Sessions of the American Diabetes Association, 2013 Chicago.
22. [22] Khetani, S.R., Bhatia, S.N., Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26:1 (2008), 120–126.
23. [23] Nelson, L.J., Treskes, P., Howie, A.F., Walker, S.W., Hayes, P.C., Plevris, J.N., Profiling the impact of medium formulation on morphology and functionality of primary hepatocytes in vitro. Sci. Rep., 3, 2013, 2735.
24. [24] Human primary hepatocytes under controlled hemodynamics elicit induction responses to drugs at clinical Cmax concentrations. Dash, A., Deering, T.G., Marukian, S., Thomas, J., Desbans, C., Alexandre, E., et al. (eds.) 52nd Annual Meeting of the Society of Toxicology, 2013 San Antonio, Texas.
25. [25] Calmy, A., Hirschel, B., Cooper, D.A., Carr, A., A new era of antiretroviral drug toxicity. Antivir. Ther. 14:2 (2009), 165–179.
26. [26] Carr, D.F., Chaponda, M., Jorgensen, A.L., Castro, E.C., van Oosterhout, J.J., Khoo, S.H., et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin. Infect. Dis. 56:9 (2013), 1330–1339.
27. [27] Eagling, V.A., Back, D.J., Barry, M.G., Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:2 (1997), 190–194.
28. [28] Ryan, C.T., New black box warning for ritonavir-boosted tipranavir. AIDS Clin. Care, 18(8), 2006, 72.
29. [29] Sulkowski, M.S., Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver Dis. 23:2 (2003), 183–194.
30. [30] Maass-Moreno, R., Rothe, C.F., Distribution of pressure gradients along hepatic vasculature. Am. J. Physiol. 272:6 Pt 2 (1997), H2826–H2832.
31. [31] Wambaugh, J., Shah, I., Simulating microdosimetry in a virtual hepatic lobule. PLoS Comput. Biol., 6(4), 2010, e1000756.
32. [32] Cooper, C.L., van Heeswijk, R.P., Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med. 8:1 (2007), 1–7.
33. [33] Hsu, A., Granneman, G.R., Witt, G., Locke, C., Denissen, J., Molla, A., et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:5 (1997), 898–905.
34. [34] Cole, B.K., Simmers, M.B., Feaver, R., Qualls, C.W. Jr., Collado, M.S., Berzin, E., et al. An in vitro cynomolgus vascular surrogate system for preclinical drug assessment and human translation. Arterioscler. Thromb. Vasc. Biol., 2015 Oct, 35(10), 2185-2195.
35. [35] Chai, X., Zeng, S., Xie, W., Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin. Drug Metab. Toxicol. 9:3 (2013), 253–266.
36. [36] Liddle, C., Goodwin, B., Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin. Liver Dis. 22:2 (2002), 115–122.
37. [37] Pascussi, J.M., Vilarem, M.J., Inflammation and drug metabolism: NF-kappB and the CAR and PXR xeno-receptors. Med. Sci. Paris. 24:3 (2008), 301–305.
38. [38] Willson, T.M., Kliewer, S.A., PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1:4 (2002), 259–266.
39. [39] Joao, E.C., Calvet, G.A., Menezes, J.A., D'Ippolito, M.M., Cruz, M.L., Salgado, L.A., et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am. J. Obstet. Gynecol. 194:1 (2006), 199–202.
40. [40] Strautnieks, S.S., Bull, L.N., Knisely, A.S., Kocoshis, S.A., Dahl, N., Arnell, H., et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20:3 (1998), 233–238.
41. [41] Flint, O.P., Noor, M.A., Hruz, P.W., Hylemon, P.B., Yarasheski, K., Kotler, D.P., et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol. Pathol. 37:1 (2009), 65–77.
42. [42] Szegezdi, E., Logue, S.E., Gorman, A.M., Samali, A., Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7:9 (2006), 880–885.
43. [43] Chan, K., Truong, D., Shangari, N., O'Brien, P.J., Drug-induced mitochondrial toxicity. Expert Opin. Drug Metab. Toxicol. 1:4 (2005), 655–669.
44. [44] Wallace, K.B., Starkov, A.A., Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 40 (2000), 353–388.
45. [45] Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5:5 (2005), 375–386.
46. [46] Faucette, S.R., Zhang, T.C., Moore, R., Sueyoshi, T., Omiecinski, C.J., LeCluyse, E.L., et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320:1 (2007), 72–80.
47. [47] Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30:7 (2002), 795–804.
48. [48] Sevrioukova, I.F., Poulos, T.L., Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues. Biochemistry 52:26 (2013), 4474–4481.
49. [49] Halladay, J.S., Wong, S., Khojasteh, S.C., Grepper, S., An ‘all-inclusive’ 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes. J. Pharmacol. Toxicol. Methods 66:3 (2012), 270–275.
50. [50] Chen, J., Farrell, G.C., Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: relevance to drug metabolism in experimental cholestasis. J. Gastroenterol. Hepatol. 11:9 (1996), 870–877.
51. [51] Gonzalez-Sanchez, E., Firrincieli, D., Housset, C., Chignard, N., Nuclear receptors in acute and chronic cholestasis. Dig. Dis. 33:3 (2015), 357–366.
52. [52] Staudinger, J., Liu, Y., Madan, A., Habeebu, S., Klaassen, C.D., Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos. 29:11 (2001), 1467–1472.
53. [53] Chiang, J.Y., Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40:3 (2004), 539–551.
54. [54] Goodwin, B., Jones, S.A., Price, R.R., Watson, M.A., McKee, D.D., Moore, L.B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6:3 (2000), 517–526.
55. [55] Cheng, J., Fang, Z.Z., Kim, J.H., Krausz, K.W., Tanaka, N., Chiang, J.Y., et al. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. J. Lipid Res. 55:3 (2014), 455–465.
56. [56] McRae, M.P., Lowe, C.M., Tian, X., Bourdet, D.L., Ho, R.H., Leake, B.F., et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther. 318:3 (2006), 1068–1075.
57. [57] Zhou, H., Gurley, E.C., Jarujaron, S., Ding, H., Fang, Y., Xu, Z., et al. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 291:6 (2006), G1071–G1080.
58. [58] Zhou, H., Pandak, W.M. Jr., Lyall, V., Natarajan, R., Hylemon, P.B., HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol. Pharmacol. 68:3 (2005), 690–700.
59. [59] Lum, P.Y., He, Y.D., Slatter, J.G., Waring, J.F., Zelinsky, N., Cavet, G., et al. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 90:4 (2007), 464–473.
60. [60] Popovic, M., Shenton, J.M., Chen, J., Baban, A., Tharmanathan, T., Mannargudi, B., et al. Nevirapine hypersensitivity. Handb. Exp. Pharmacol. 196 (2010), 437–451.
61. [61] Keane, N.M., Pavlos, R.K., McKinnon, E., Lucas, A., Rive, C., Blyth, C.C., et al. HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. AIDS 28:13 (2014), 1891–1901.
62. [62] Cui, J., Zhu, L., Xia, X., Wang, H.Y., Legras, X., Hong, J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 141:3 (2010), 483–496.
63. [63] Staehli, F., Ludigs, K., Heinz, L.X., Seguin-Estevez, Q., Ferrero, I., Braun, M., et al. NLRC5 deficiency selectively impairs MHC class I-dependent lymphocyte killing by cytotoxic T cells. J. Immunol. 188:8 (2012), 3820–3828.
64. [64] Andre, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B.L. Jr., Cerundolo, V., et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. U. S. A. 95:22 (1998), 13120–13124.
65. [65] Ulianich, L., Terrazzano, G., Annunziatella, M., Ruggiero, G., Beguinot, F., Di Jeso, B., ER stress impairs MHC class I surface expression and increases susceptibility of thyroid cells to NK-mediated cytotoxicity. Biochim. Biophys. Acta 1812:4 (2011), 431–438.
66. [66] Zhang, Z., Li, X., Liu, G., Gao, L., Guo, C., Kong, T., et al. High insulin concentrations repress insulin receptor gene expression in calf hepatocytes cultured in vitro. Cell. Physiol. Biochem. 27:6 (2011), 637–640.
67. [67] Parker, R.A., Flint, O.P., Mulvey, R., Elosua, C., Wang, F., Fenderson, W., et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol. Pharmacol. 67:6 (2005), 1909–1919.
68. [68] Riddle, T.M., Kuhel, D.G., Woollett, L.A., Fichtenbaum, C.J., Hui, D.Y., HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276:40 (2001), 37514–37519.
69. [69] Sterling, R.K., Contos, M.J., Smith, P.G., Stravitz, R.T., Luketic, V.A., Fuchs, M., et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 47:4 (2008), 1118–1127.
70. [70] Caron, M., Auclairt, M., Vissian, A., Vigouroux, C., Capeau, J., Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir. Ther. 13:1 (2008), 27–38.
71. [71] Negredo, E., Miro, O., Rodriguez-Santiago, B., Garrabou, G., Estany, C., Masabeu, A., et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin. Infect. Dis. 49:6 (2009), 892–900.